澳大利亚与新西兰胸科学会:慢性新生儿肺病婴儿出NICU后呼吸管理立场声明
该立场声明针对慢性新生儿肺病(CNLD)婴儿出院后的呼吸管理提供指导,重点阐述补充氧疗的作用与流程。推荐夜间血氧饱和度(SpO2)目标均值下限为93-95%,且低于90%的时间占比小于5%;出院前需评估短暂断氧安全性,多数婴儿需氧量≤0.5 L/min才可出院;减氧期间推荐持续夜间血氧监测;帕利珠单抗可用于减少RSV感染住院。
要点
- 夜间血氧目标均值下限93-95%,低于90%时间占比<5%。
- 多数CNLD婴儿需氧量≤0.5 L/min才可出院,出院前评估断氧安全性。
- 减氧期间推荐持续夜间血氧监测,帕利珠单抗可减少RSV住院。
核心结论
- CNLD婴儿出院后补充氧疗需个体化,兼顾肺动脉高压、早产儿视网膜病和生长状况等合并症。
研究设计与样本
- 澳大利亚与新西兰胸科学会制定的立场声明,针对慢性新生儿肺病(CNLD)婴儿出NICU后的呼吸管理提供指导。
主要发现
- 低流量补充氧疗广泛用于存在空气低氧的CNLD婴儿以促进出院,但最适目标氧饱和度证据缺乏。
- 家庭监测、氧疗滴定和减氧的指导数据极少。
关键数值与推荐
- 推荐夜间血氧监测SpO2均值目标下限为93-95%,且总记录时间中低于90%的比例小于5%。
- 出院前应评估短暂断氧安全性,多数CNLD婴儿需氧量≤0.5 L/min才可出院。
- 减氧期间推荐持续夜间血氧监测评估氧合。
- 帕利珠单抗被认为安全有效,可减少该群体RSV感染住院。
临床怎么用
- 适用于儿科医生、新生儿科医生、呼吸与睡眠医生及全科医生管理CNLD婴儿。
- 出院前评估断氧安全性,多数需氧量≤0.5 L/min才可出院。
- 减氧期间采用持续夜间血氧监测,目标SpO2均值93-95%且低于90%时间<5%。
局限性
- 最适最低平均目标氧饱和度证据缺乏。
- 家庭监测、氧疗滴定和减氧的指导数据极少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic neonatal lung disease (CNLD) is defined as continued need for any form of respiratory support (supplemental oxygen and/or assisted ventilation) beyond 36 weeks PMA. Low-flow supplemental oxygen facilitates discharge from hospital of infants with CNLD who are hypoxic in air and is widely used despite lack of evidence on the most appropriate minimum mean target oxygen saturations. Furthermore, there are minimal data to guide the home monitoring, titration or weaning of supplemental oxygen in these infants. The purpose of this position statement is to provide a guide for the respiratory management of infants with CNLD, with special emphasis on role and logistics of supplemental oxygen therapy beyond the NICU stay. Reflecting a variety of clinical practices and infant comorbidities (presence of pulmonary hypertension, retinopathy of prematurity and adequacy of growth), it is recommended that the minimum mean target range for SpO2 during overnight oximetry to be 93-95% with less than 5% of total recording time to be below 90% SpO2 . Safety of short-term disconnection from supplemental oxygen should be assessed before discharge, with majority of infants with CNLD not ready for discharge until supplemental oxygen requirement is ≤0.5 L/min. Sleep-time assessment of oxygenation with continuous overnight oximetry is recommended when weaning supplemental oxygen. Palivizumab is considered safe and effective for the reduction of hospital admissions with RSV infection in this group. This statement would be useful for paediatricians, neonatologists, respiratory and sleep physicians and general practitioners managing children with CNLD.
引用
- Kapur N, Nixon G, Robinson P, et al. Respiratory management of infants with chronic neonatal lung disease beyond the NICU: A position statement from the Thoracic Society of Australia and New Zealand. Respirology. 2020. PMID: 32510776. doi:10.1111/resp.13876
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。